Mr Jose Calle Gardo has led an illustrious career with over 25 years of broad business and management experience in the medical devices industry, having served in various vice president and managerial roles at Abbott, Eli Lilly, and Guidant. He led the global team that developed and commercialized Xience a family of drug eluting stents (DES) and a market leader for the treatment of coronary artery disease with global sales of more than $1.6 billion while serving as Vice President and General Manager of Drug Eluting Stents Vascular Intervention at Guidant based in Santa Clara, CA, U.S.A.
As Vice President of Abbott Vascular based in Brussels, he later led the commercial introduction of Bioresorbable Vascular Scaffolds (ABSORB) and MitraClip, the world's first percutaneous mitral valve repair therapy. During his earlier years with Abbott, he spearheaded the integration of Guidant and Abbott Vascular Devices in 2006 and managed the international operations of Abbott Vascular outside the U.S. between 2011 and 2012.
http://infopub.sgx.com/Apps?A=COW_CorpAnnouncement_Content&B=AnnouncementToday&F=KD5PXZXH5ET6YSPZ
𝐀𝐬𝐤 𝐌𝐞 𝐀𝐧𝐲 𝐒𝐆 𝐒𝐭𝐨𝐜𝐤𝐬 𝐓𝐢𝐤𝐭𝐨𝐤 𝐑𝐞𝐩𝐥𝐚𝐲
-
𝐀𝐬𝐤 𝐌𝐞 𝐀𝐧𝐲 𝐒𝐆 𝐒𝐭𝐨𝐜𝐤𝐬 𝐓𝐢𝐤𝐭𝐨𝐤 𝐑𝐞𝐩𝐥𝐚𝐲
>> https://youtu.be/3m63nvwaF14
See below for the Most Popular US stocks asked and ...
3 days ago